ValuEngine downgraded shares of Synlogic (NASDAQ:SYBX) from a sell rating to a strong sell rating in a report published on Friday morning.
Other research analysts have also recently issued reports about the company. Wedbush assumed coverage on Synlogic in a report on Monday, November 27th. They issued an outperform rating and a $20.00 price objective on the stock. Zacks Investment Research cut Synlogic from a hold rating to a sell rating in a report on Wednesday, November 22nd. Finally, Piper Jaffray Companies assumed coverage on Synlogic in a report on Monday, January 29th. They issued an overweight rating and a $16.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $18.75.
Shares of Synlogic (NASDAQ SYBX) opened at $9.95 on Friday. The stock has a market capitalization of $162.85 and a P/E ratio of -2.13. Synlogic has a 52-week low of $8.76 and a 52-week high of $23.00.
Synlogic (NASDAQ:SYBX) last posted its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($1.16). analysts forecast that Synlogic will post -5.5 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Synlogic (SYBX) Downgraded by ValuEngine” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2018/02/06/synlogic-sybx-downgraded-by-valuengine.html.
Synlogic Company Profile
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.